2611005574
  • Open Access
  • Case Report

Facial Discoid Dermatosis Mimicking Vitiligo in a South Asian Woman with Fitzpatrick Type IV Skin: Response to Methotrexate and Topical Ruxolitinib

  • Simal A. Qureshi 1,*,   
  • Andrew Ferrier 2,   
  • Katherine Lach 3 and 
  • Eunice Y. Chow 2

Received: 05 August 2026 | Revised: 29 October 2026 | Accepted: 04 November 2026 | Published: 17 November 2026

Abstract

Facial discoid dermatosis (FDD) is a rare, recently described condition characterized by persistent facial lesions that are often refractory to topical and systemic treatments. It typically presents as annular, well-demarcated papules and plaques with fine scale on the face, with a histopathologic pattern resembling pityriasis rubra pilaris. The differential diagnosis is broad, including seborrheic dermatitis, psoriasis, lupus, rosacea, and mycosis fungoides, making diagnosis challenging. In darker skin, FDD may present as hypopigmented macules that are mistaken for vitiligo or post-inflammatory hypopigmentation. Treatment options for FDD remain limited, with few reports of successful interventions. We present a 40-year-old South Asian woman with Fitzpatrick type IV skin and a 10-year history of hypopigmented facial lesions initially diagnosed as vitiligo. We describe the dermoscopic findings, including retained pigmented vellus hairs, and her improvement with oral methotrexate combined with topical ruxolitinib 1.5% cream, with continued repigmentation on topical ruxolitinib alone. FDD should be considered in the differential diagnosis of treatment-resistant facial hypopigmentation in darker skin.

References 

  • 1.

    Ko, C.J.; Heald, P.; Antaya, R.J.; et al. Facial discoid dermatosis. Int. J. Dermatol. 2010, 49, 189–192. https://doi.org/10.1111/j.1365-4632.2009.04206.x.

  • 2.

    Fera, C.; Chamaillard, M.; Beylot-Barry, M.; et al. Facial discoid dermatosis, a still unknown entity. Acta Derm. Venereol. 2025, 105, adv40911. https://doi.org/10.2340/actadv.v105.40911.

  • 3.

    Lin, R.L.; Szepietowski, J.C.; Schwartz, R.A. Tinea faciei, an often deceptive facial eruption. Int. J. Dermatol. 2004, 43, 437–440. https://doi.org/10.1111/j.1365-4632.2004.02339.x.

  • 4.

    Ziebart, R.L.; Newcomer, J.B.; Cull, D.B.; et al. Facial discoid dermatosis: Retrospective clinical and immunohistopathologic cohort study. Int. J. Dermatol. 2026, 65, 1919–1922. https://doi.org/10.1111/ijd.70505.

  • 5.

    Amarnani, R.; Hughes, S.; Morris-Jones, R.; et al. Persistent facial discoid dermatosis successfully treated with topical calcipotriol. Clin. Exp. Dermatol. 2022, 47, 229–231. https://doi.org/10.1111/ced.14945.

  • 6.

    Bohdanowicz, M.; DeKoven, J.G. Improvement in facial discoid dermatosis with calcipotriol/betamethasone ointment and low-dose acitretin. Clin. Exp. Dermatol. 2018, 43, 820–821. https://doi.org/10.1111/ced.13611.

  • 7.

    Allegue, F.; Fachal, C.; Iglesias, B.; et al. Facial discoid dermatosis: A new variant of pityriasis rubra pilaris? Actas Dermosifiliogr. 2022, 113, 728–731. https://doi.org/10.1016/j.ad.2021.01.006.

  • 8.

    Murtas, A.; Mugheddu, C.; Pilloni, L.; et al. Efficacy of calcipotriol/betamethasone ointment in facial discoid dermatosis. JEADV Clin. Pract. 2025, 4, 544–551. https://doi.org/10.1002/jvc2.625.

  • 9.

    Huang, Y.W.; Tsai, T.F. Topical rapamycin (sirolimus) for the treatment of facial discoid dermatosis. Eur. J. Dermatol. 2024, 34, 201–203. https://doi.org/10.1684/ejd.2024.4651.

  • 10.

    Rodríguez-Troncoso, M.; De la Torre-Gomar, F.J.; Pegalajar-García, M.D.; et al. Oral isotretinoin for facial discoid dermatosis: Effectiveness, safety, and clinical suitability. Case report of complete response and literature review. Case Rep. Dermatol. 2025, 17, 362–369. https://doi.org/10.1159/000547263.

  • 11.

    Rypka, K.J.; Fulk, T.S.; Afsaneh, A.; et al. Improvement of facial discoid dermatosis with ustekinumab treatment. JAMA Dermatol. 2022, 158, 1079–1080. https://doi.org/10.1001/jamadermatol.2022.2478.

  • 12.

    Yi, R.C.; Su, J.J.; Powell, M.R.; et al. Improvement of treatment resistant facial discoid dermatosis with secukinumab. JAAD Case Rep. 2026, 69, 56–58. https://doi.org/10.1016/j.jdcr.2025.12.024.

  • 13.

    Garcia, A.; Archimbaud, J.; Kanitakis, J.; et al. Facial discoid dermatosis successfully treated with topical ruxolitinib: A case report. JAAD Case Rep. 2026, 77, 66–69. https://doi.org/10.1016/j.jdcr.2026.07.039.

  • 14.

    Condal, L.; Quer, A.; Ferrándiz, C.; et al. Facial discoid dermatosis: An enigmatic disease. Actas Dermosifiliogr. 2021, 112, 934–935. https://doi.org/10.1016/j.ad.2020.01.009.

  • 15.

    Incyte Corporation. OPZELURA (Ruxolitinib Cream): Product Monograph Including Patient Medication Information [Internet]. 2026. Available online: https://health-products.canada.ca/dpd-bdpp/info?code=104109&lang=eng (accessed on 27 October 2026).

  • 16.

    Gan, E.Y.; Ng, S.K.; Goh, C.L.; et al. Recalcitrant psoriasiform dermatosis of the face: Is it related to pityriasis rubra pilaris? J. Cutan. Pathol. 2018, 45, 491–497. https://doi.org/10.1111/cup.13148.

  • 17.

    Welborn, M.; Fletcher, D.; Motaparthi, K. Atrophy of sebaceous lobules in facial discoid dermatosis: A link to psoriasis and seborrheic dermatitis? J. Cutan. Pathol. 2022, 49, 320–323. https://doi.org/10.1111/cup.14190.

  • 18.

    Zygadło, J.; Blicharz, L.; Czuwara, J.; et al. Facial discoid dermatosis imaging with line-field confocal optical coherence tomography and reflectance confocal microscopy: A case report and literature review. J. Pers. Med. 2026, 16, 360. https://doi.org/10.3390/jpm16070360.

  • 19.

    Moulonguet, I.; Matard, B. Familial facial discoid dermatosis. Ann. Dermatol. Venereol. 2025, 152, 103385. https://doi.org/10.1016/j.annder.2025.103385.

  • 20.

    Vieira-Granja, B.; Magina, S. Janus kinase inhibitors in dermatology: A review. Port. J. Dermatol. Venereol. 2023, 81, 1–20. https://doi.org/10.24875/PJDV.22000037.

  • 21.

    Dogra, S.; Sharma, A.; Mehta, H.; et al. Emerging role of topical Janus kinase inhibitors in dermatological disorders: A review. Clin. Exp. Dermatol. 2023, 48, 1102–1112. https://doi.org/10.1093/ced/llad188.

  • 22.

    Kang, C. Ruxolitinib cream 1.5%: A review in non-segmental vitiligo. Drugs 2024, 84, 579–586. https://doi.org/10.1007/s40265-024-02027-2.

  • 23.

    Lallas, A.; Argenziano, G.; Apalla, Z.; et al. Dermoscopic patterns of common facial inflammatory skin diseases. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 609–614. https://doi.org/10.1111/jdv.12146.

  • 24.

    Yang, Y.; Morriss, S.; Rodrigues, M. Dermoscopy in vitiligo, diagnostic clues and markers of disease activity: A review of the literature. Clin. Exp. Dermatol. 2024, 49, 969–975. https://doi.org/10.1093/ced/llad365.

Share this article:
How to Cite
Qureshi, S. A.; Ferrier, A.; Lach, K.; Chow, E. Y. Facial Discoid Dermatosis Mimicking Vitiligo in a South Asian Woman with Fitzpatrick Type IV Skin: Response to Methotrexate and Topical Ruxolitinib. Dermatology and Skin Science 2026, 1 (3), 12. https://doi.org/10.53941/dss.2026.100012.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.
Article Metrics
7
Article Views
0
Citations